Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Update

Bioxytran, Inc. (OTCMKTS:BIXT) saw a large increase in short interest in January. As of January 30th, there was short interest totaling 5,695 shares, an increase of 1,798.3% from the January 15th total of 300 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average trading volume of 541,049 shares, the days-to-cover ratio is presently 0.0 days. Based on an average trading volume of 541,049 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are short sold.

Bioxytran Price Performance

Shares of Bioxytran stock opened at $0.05 on Wednesday. The stock has a market capitalization of $5.30 million, a price-to-earnings ratio of -1.57 and a beta of 1.99. The business has a 50-day moving average of $0.07 and a 200 day moving average of $0.07. Bioxytran has a 12 month low of $0.03 and a 12 month high of $0.23.

About Bioxytran

Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.

Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.